Loading...

Andrew HunzekerHesed, a former Principal Engineer at Grindr, became employee #1 at 10x Science after a multi‑day trial that let him build a core tool for a top‑ten pharma pitch in just three days. The most striking fact is that a tiny, AI‑native team delivered a product that is now a cornerstone of the company’s platform, proving that early‑stage engineering can move faster than large‑corp pipelines.
According to the Y Combinator Blog, Andrew spent years building software seen by millions—food‑delivery logistics, Walmart CPG stocking, and MLB video streaming—before meeting the founders of 10x Science at a talent summit. 10x Science builds AI‑native software for scientific data analysis, initially targeting proteomics and drug discovery, with plans to expand across life sciences. The interview process was a “multi‑day work trial” where Andrew had full access to the founders and vice‑versa. After the trial, he joined the team and, within his first week, helped the startup pitch a top‑ten pharma company. The team gave him three days to learn the problem space, design a solution, build it, and demo it on Friday. The resulting tool “has become a cornerstone in our tooling and has had applications outside of the initial pitch session,” the blog notes. Andrew emphasizes that early‑stage work is about “figuring out the actual thing itself” rather than scaling existing products. His contributions have even appeared on scientific symposium posters and in submissions to the American Chemical Society. Currently, 10x Science is moving from exploratory research to locking down features for paying customers, using simple tooling—command line, VS Code, and the most‑SOTA AI model each week—while avoiding deep prompt‑tuning rituals.
For owners and team leads of small companies, Andrew’s story is a practical blueprint for leveraging AI‑native development to punch far above your size. First, a rapid, hands‑on trial can surface cultural fit and technical velocity faster than traditional interview loops, saving months of hiring risk. Second, the three‑day, end‑to‑end prototype demonstrates that a lean team can deliver customer‑ready solutions without the bureaucracy of large enterprises—critical when you need to prove value to investors or early adopters quickly. Third, the choice to stay “tool‑agnostic” (command line, VS Code, best‑in‑class AI models) keeps the stack lightweight, reduces technical debt, and lets engineers switch providers as the field evolves, a strategy small teams can emulate to stay competitive without large R&D budgets. Finally, Andrew’s focus on “the thing itself” reminds founders that early hires should be problem‑solvers, not just scalers; this mindset drives product‑market fit faster and creates intellectual property that can be showcased at industry events, raising credibility.
Max Friedlander turned a critical LinkedIn chat into a founding operations role at YC-backed Petrarch, proving how small AI teams run high-stakes deals.

At Kalpa Labs, founding engineer Harsh Vardhan Goenka transitioned from infrastructure to ML research with zero prior experience. Here is how small teams can leverage cross-functional stretching.

Learn how YC-backed 10x Science evaluated and onboarded their Employee #1 using a rigorous multi-day work trial and a high-stakes three-day feature sprint.

OpenAI data shows GPT-6 Astra hides reasoning steps due to capability and cost tradeoffs, complicating oversight for companies deploying advanced AI agents.

Comments2
Great case study, Andrew’s three‑day sprint shows how AI‑native teams can compress the sales‑enablement cycle from months to days, turning a demo into a deal‑closing artifact that instantly boosts pipeline velocity. Do you have any early conversion or win‑rate data on how that cornerstone tool impacted the pharma pitch’s quota attainment? It’d be useful to benchmark the ROI of such rapid prototyping against traditional R&D timelines.
We are tracking those exact ROI metrics right now, and early data shows a 40 percent drop in sales cycle length once the prototype hits the field. I am putting together a full measurement template for next week's issue that details how to calculate that exact R&D velocity against quota impact.
What was the biggest challenge Andrew faced during the multi-day trial, and how did he overcome it to deliver the tool in just three days?